RWD Sources – How the Genesis of Your Data Determines What Questions You Can Answer
.jpg?version=1&modificationDate=1709900857818&cacheVersion=1&api=v2&width=933&height=195)
| Catch up Here! |
|---|
| Community Forum: RWD Sources – How the Genesis of Your Data Determines What Questions You Can Answer |
|---|
RWD Sources – How the Genesis of Your Data Determines What Questions You Can Answer When considering sources of RWD, it is important to consider more than just the number of available patients. Recently released guidance from the FDA encourages researchers to build accurate, complete and traceable real-world datasets. Combining data from structured and unstructured electronic health record data, closed claims, and other sources is essential to building the patient journey. In our October Community Forum, we will explore two different angles of RWD sourcing from the provider’s point of view:
Come and join us for what promises to be another very interesting Community Forum! |
| Presenter | Bio |
|---|---|
| Matthew Reynolds, Azimuth Research Group Matthew W. Reynolds, PhD, FISPE is Senior Vice President, Scientific Affairs at Azimuth Research Group (ARG). His responsibilities include scientific oversight of all Azimuth research studies as well as leading the scientific collaboration with ARG’s clients and strategic partners. He has more than 25 years of pharmaceutical research experience. Dr Reynolds previously served as the Head of Scientific Engagement at Flatiron Health, providing expert scientific insights as part of the scientific services division. Prior to that, he served as the VP of Scientific Affairs, reporting to the Chief Scientific Officer at IQVIA, where he focused on innovative solutions for real-world evidence on effectiveness and safety. He served as the Vice President of Epidemiology at Evidera for over 15 years, where he led a team of over 40 epidemiology staff conducting fit-for-purpose real-world data projects, while managing client initiatives and partnerships. He has held positions at AstraZeneca as Associate Director of Cardiovascular Epidemiology, at Pharmacia Corporation (formerly Searle Pharmaceutical) as a pharmacoepidemiologist and senior analyst, and at the School of Medicine at the University of Maryland, Baltimore. Dr Reynolds also founded and chaired the Database Special Interest Group for the International Society of Pharmacoepidemiology (ISPE). He has published over 60 peer-reviewed papers and has led or presented extensively over his career at several conferences and congresses. Dr Reynolds earned his graduate and doctoral degrees in epidemiology and preventive medicine from the University of Maryland, Baltimore in January 2000. |
| Timothy Wolfe, Verantos Tim Wolfe is Vice President of Product at Verantos. Tim is a data-driven product leader focused on harnessing healthcare data to drive tangible value for customers. Tim previously served as Vice President of Product at Syapse, where he launched multiple SaaS real-world data products from zero to multi-million-dollar annual recurring revenue. He has successfully led teams of product managers, data product managers, design, and business analytics in driving the full product life cycle. Prior to Syapse, Tim led centralised AI services for IBM Watson Health, building internal capabilities for diverse market segments including life sciences, government, imaging and value-based care. He also previously served as Data Coordinator at Innovations for Poverty Action, where he managed data collection, storage and analysis in rural Kenya on the largest water, sanitation and hygiene randomised controlled trial ever conducted (funded by the Bill & Melinda Gates Foundation). Tim holds an MBA from MIT Sloan School of Management and a bachelor of arts in human biology from Stanford University. |
